[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MXPA03008423A - Agonistas del receptor nicotinico para el tratamiento de enfermedades inflamatorias. - Google Patents

Agonistas del receptor nicotinico para el tratamiento de enfermedades inflamatorias.

Info

Publication number
MXPA03008423A
MXPA03008423A MXPA03008423A MXPA03008423A MXPA03008423A MX PA03008423 A MXPA03008423 A MX PA03008423A MX PA03008423 A MXPA03008423 A MX PA03008423A MX PA03008423 A MXPA03008423 A MX PA03008423A MX PA03008423 A MXPA03008423 A MX PA03008423A
Authority
MX
Mexico
Prior art keywords
receptor agonists
treatment
inflammatory diseases
nicotinic receptor
agonists
Prior art date
Application number
MXPA03008423A
Other languages
English (en)
Inventor
Cormier Yvon
Original Assignee
Univ Laval
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Laval filed Critical Univ Laval
Publication of MXPA03008423A publication Critical patent/MXPA03008423A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invencion se relaciona al uso de los agonistas del receptor de nicotina para tratar las enfermedades inflamatorias, incluyendo una variedad de enfermedades pulmonares. Tales agonistas tienen pocos efectos secundarios que otros farmacos anti-inflamatorios, tales como esteroides. Ademas, estos agonistas pueden ser utiles solos o en combinacion con otros farmacos anti-inflamatorios para aliviar las enfermedades pulmonares.
MXPA03008423A 2001-03-23 2002-03-25 Agonistas del receptor nicotinico para el tratamiento de enfermedades inflamatorias. MXPA03008423A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002341952A CA2341952A1 (en) 2001-03-23 2001-03-23 Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
PCT/CA2002/000412 WO2002076434A2 (en) 2001-03-23 2002-03-25 Nicotinic receptor agonists for the treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
MXPA03008423A true MXPA03008423A (es) 2004-03-19

Family

ID=4168679

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03008423A MXPA03008423A (es) 2001-03-23 2002-03-25 Agonistas del receptor nicotinico para el tratamiento de enfermedades inflamatorias.

Country Status (18)

Country Link
US (3) US7601720B2 (es)
EP (1) EP1370264B1 (es)
JP (1) JP4377586B2 (es)
CN (1) CN100528159C (es)
AT (1) ATE378051T1 (es)
AU (1) AU2002249023B2 (es)
BR (1) BR0208305A (es)
CA (1) CA2341952A1 (es)
DE (1) DE60223508T2 (es)
DK (1) DK1370264T3 (es)
ES (1) ES2295331T3 (es)
IL (1) IL157757A0 (es)
MX (1) MXPA03008423A (es)
NO (1) NO331674B1 (es)
NZ (1) NZ528042A (es)
PL (1) PL207880B1 (es)
RU (1) RU2299731C2 (es)
WO (1) WO2002076434A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
CA2341952A1 (en) 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
US20050130990A1 (en) * 2001-03-23 2005-06-16 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US7045534B2 (en) * 2002-02-12 2006-05-16 The Board Of Trustees Of The Leland Stanford Junior University Methods of reducing angiogenesis
US8039459B2 (en) 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8557804B2 (en) 2002-03-25 2013-10-15 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US20040010018A1 (en) * 2002-05-15 2004-01-15 Rueter Lynne E. Treatment of neuropathic pain
US7238715B2 (en) 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
PL364348A1 (en) 2004-01-12 2005-07-25 PHARMENA Sp.z o.o. Application of quaternary pyridine salts as vessel protection agent
PL1773779T3 (pl) * 2004-07-15 2014-04-30 Univ Laval Agoniści receptora nikotynowego do leczenia chorób zapalnych
US9029557B2 (en) 2004-12-07 2015-05-12 The Regents Of The University Of California Labeled A4B2 ligands and methods therefor
WO2006086068A1 (en) 2004-12-07 2006-08-17 The Regents Of The University Of California Labeled alpha-4-beta-2 ligands and methods therefor
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
US20070167526A1 (en) * 2005-12-19 2007-07-19 Xiaoming Zhang Topical mecamylamine formulations for ocular administration and uses thereof
EP2801360B1 (en) * 2006-05-08 2018-04-25 Arturo Solis Herrera The use of nicotine for the treatment of post traumatic bleeding in humans
CA2794097C (en) * 2010-03-23 2016-08-09 Rock Creek Pharmaceuticals, Inc. Use of anatabine to treat inflammation and methods of synthesizing anatabine
US8207346B2 (en) 2010-03-23 2012-06-26 Rock Creek Pharmaceuticals, Inc. Methods of synthesizing anatabine
JP5934796B2 (ja) 2011-08-29 2016-06-15 アールシーピー ディベロップメント インコーポレイテッド 抗炎症補助のための製品
EP3125903B1 (en) 2014-04-03 2018-12-19 Université Laval Method for use of homopiperazinium compounds in the treatment of cancer
RU2593585C1 (ru) * 2015-06-26 2016-08-10 Общество с ограниченной ответственностью "Ритек-Фарма" Способ лечения табакокурения и других форм никотиновой зависимости, а также профилактики рецидивов табакокурения
CN113992687B (zh) * 2021-12-28 2022-04-08 浙江宇视科技有限公司 智能业务集群调度方法、装置、电子设备及存储介质

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2594296A (en) * 1948-06-24 1952-04-29 Aerosol Corp Lobeline aerosol dilating medicament
US2778772A (en) 1952-11-04 1957-01-22 Parke Davis & Co Dimethyl phenyl piperazinium iodide compositions and process for stimulation of the autonomic ganglion system
US3402039A (en) 1966-12-05 1968-09-17 Dow Chemical Co Piperazinium salts as plant stunting agents
US5977144A (en) 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
CA2204915A1 (en) * 1994-11-11 1996-05-23 Seiichi Uchida Optically active compound
WO2000023062A2 (en) 1998-10-20 2000-04-27 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
US5846983A (en) 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
RU2127123C1 (ru) 1996-06-04 1999-03-10 Московское производственное химико-фармацевтическое объединение им.Н.А.Семашко Противоастматическое лекарственное средство в виде таблеток и способ получения таблеток
GB9614902D0 (en) 1996-07-16 1996-09-04 Rhodes John Sustained release composition
US5981549A (en) 1997-02-14 1999-11-09 Synapse Pharmaceutical International Method for controlling or alleviating the symptoms of respiratory disease and allergies
EE04588B1 (et) 1997-10-27 2006-02-15 Neurosearch A/S Heteroarüüldiasatsükloalkaanid kui atsetüülkoliini nikotiinretseptorite kolinergilised ligandid, nende kasutamine ravimitena ning neid sisaldav farmatseutiline kompositsioon
EP1159003B1 (en) * 1999-03-02 2010-11-17 Centocor, Inc. Anti-tnf alpha antibodies in therapy of steroid resistant asthma
CA2377698A1 (en) 1999-06-21 2000-12-28 Bristol-Myers Squibb Company Dihydropyrazine derivatives as npy antagonists
SE0001075D0 (sv) 1999-09-01 2000-03-27 Laszlo Bense Användning av åtminstone ett nikotinbaserat ämne och/eller ett ur detta ämne framställt ämne för tillverkning av ett medikament samt förfarande för behandling av obstruktiva lungsjukdomar
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US6610713B2 (en) 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
DE60132710T2 (de) * 2000-12-01 2008-06-12 Neurosearch A/S 3-substituierte chinuclidine und ihre verwendung als nikotinische agonisten
US20020160988A1 (en) 2001-02-20 2002-10-31 Israel Institute For Biological Research Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof
US7891578B2 (en) 2001-03-22 2011-02-22 Battelle Memorial Institute Liquid formations for electrohydrodymanic spraying containing polymer and suspended particles
US20050130990A1 (en) 2001-03-23 2005-06-16 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
CA2341952A1 (en) 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
GB2381750A (en) 2001-10-10 2003-05-14 Inspire Pharmaceuticals Inc Treatment for enhancing joint lubrication
US20030236287A1 (en) 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
TW200412945A (en) 2002-10-25 2004-08-01 Upjohn Co Quaternary ammonium compounds
US6946486B2 (en) 2002-10-29 2005-09-20 Pharmacia & Upjohn Co. Quaternary ammonium compounds
BR0315747A (pt) 2002-10-29 2005-09-06 Pharmacia & Upjohn Co Llc Compostos de amÈnio quaternário como antagonistas de receptor muscarìnico
US20050075323A1 (en) 2003-03-05 2005-04-07 Pfizer Inc Beta3 adrenergic receptor agonists and uses thereof
FR2852830B1 (fr) 2003-03-24 2008-04-18 Oreal Composition de teinture des fibres keratiniques comprenant un derive de para-phenylenediamine cationique substitue par un cycle diazacyclohexane ou diazacycloheptane
BRPI0409370A (pt) 2003-04-15 2006-04-25 Pharmacia & Upjohn Co Llc compostos de amÈnio quaternário e seus usos como agentes antimuscarìnicos
PL1773779T3 (pl) 2004-07-15 2014-04-30 Univ Laval Agoniści receptora nikotynowego do leczenia chorób zapalnych

Also Published As

Publication number Publication date
US8377936B2 (en) 2013-02-19
DK1370264T3 (da) 2008-03-17
US20100227871A1 (en) 2010-09-09
WO2002076434A3 (en) 2003-07-17
JP4377586B2 (ja) 2009-12-02
EP1370264A2 (en) 2003-12-17
WO2002076434A2 (en) 2002-10-03
CN1498108A (zh) 2004-05-19
AU2002249023B2 (en) 2006-02-02
JP2004523588A (ja) 2004-08-05
ES2295331T3 (es) 2008-04-16
IL157757A0 (en) 2004-03-28
BR0208305A (pt) 2004-03-09
NO20034185L (no) 2003-11-24
RU2299731C2 (ru) 2007-05-27
US7601720B2 (en) 2009-10-13
NZ528042A (en) 2005-10-28
DE60223508D1 (de) 2007-12-27
CN100528159C (zh) 2009-08-19
EP1370264B1 (en) 2007-11-14
NO20034185D0 (no) 2003-09-19
NO331674B1 (no) 2012-02-20
ATE378051T1 (de) 2007-11-15
DE60223508T2 (de) 2008-09-25
RU2003131178A (ru) 2005-04-10
CA2341952A1 (en) 2002-09-23
PL365224A1 (en) 2004-12-27
US20040132737A1 (en) 2004-07-08
US20110245270A1 (en) 2011-10-06
PL207880B1 (pl) 2011-02-28

Similar Documents

Publication Publication Date Title
MXPA03008423A (es) Agonistas del receptor nicotinico para el tratamiento de enfermedades inflamatorias.
HK1096392A1 (en) Substituted heterocycles
MY158162A (en) 5-membered heterocycle-based p38 kinase inhibitors
PT1202736E (pt) Nicotina na angiogénese e vasculogénese terapêuticas
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
TW200637522A (en) Skin treatment articles and methods
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
UA85597C2 (ru) Четвертичные соли как антагонисты ccr2
TW200633980A (en) Pyridones useful as inhibitors of kinases
TW200510416A (en) P38 inhibitors and methods of use thereof
WO2003084539A3 (en) New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
TW200510343A (en) Substituted dihydroquinazolines
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
TNSN07263A1 (en) Substituted 4-phenyl tetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
TW200621765A (en) Substituted phenylaminothiazoles and their use
TW200726763A (en) Novel compound
WO2002072571A8 (en) Pyridinyl pyrazoles useful for the treatment of copd
SI1492773T1 (sl) 4-(heterociklil)-benzensulfoksiminske spojine za zdravljenje vnetja
HK1112228A1 (en) Substituted azachinzolines having an antiviral action
ATE475651T1 (de) Aryl-substituierte heterozyklen und ihre verwendung
WO2007100430A3 (en) Cytisine and acetylcholine analogs and methods of treating mood disorders
BG106748A (en) Method and compositions for treating pulmonary diseases
NO20006699D0 (no) Forbindelser med veksthormonfrigjörende egenskaper
SE0103210D0 (sv) New formulations and use thereof

Legal Events

Date Code Title Description
FG Grant or registration